New Technology May Help Eliminate Deadly Type of Esophageal Cancer
Barretts esophagus is a condition in which the tissue lining the esophagusthe muscular tube that connects the mouth to the stomachis replaced by tissue that is similar to the lining of the intestine. Barretts is commonly found in people with chronic gastroesophageal reflux disease, often called GERD or acid reflux, and can lead to a deadly type of esophageal cancer.
Nathan Schmulewitz, MD, assistant professor of digestive diseases at the University of Cincinnati (UC), is using a new technologycalled HALOwhich uses radiofrequency ablation to burn away this lining.
He says
Previously, the only way to cure Barretts was through surgerytaking out the portion of the esophagus that was affected and pulling the stomach into the chestor Photodynamic therapy, PDT, which also involves burning the esophageal lining, he says, noting that PDT causes a deeper burn, predisposing the patient to higher complication rates and possibly leading to severe skin burns. This new technology is a big deal. It is essentially curing the disease with a minimally-invasive procedure.
Radiofrequency ablationwhich has been used to destroy tumors in other organsuses an electrode to burn the circumferential lining of the esophagus away.
It is very safe and is done as an outpatient endoscopy procedure, Schmulewitz says. Our goal is to eradicate a known, precancerous condition.
Patients with Barretts esophagus who have shown precancerous changes on biopsy samples as well as those who have not yet demonstrated precancerous changes are candidates for the procedure.
Schmulewitz has no financial interests in Barrx, the company that manufactures the HALO ablation technology.
Doctors at University Hospital are using a new technology that could help eliminate the risk of cancer for patients with Barrett's esophagus.
Nathan Schmulewitz, MD, department of internal medicine, division of digestive diseases
Tags
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.